Congratulations to Joseph Newman, who was presented with the ELF Travel grant 10 September at the ERS Congress in Vienna for the best abstract in patient centred research entitled 'The Pulmonary Hypertension Global Patient Survey (PH GPS): an overview and results'. 

The PVRI Innovative Drug Development Initiative (IDDI) Access to Care Workstream created the Access to Care poster which was presented at the PHA Conference in Indianapolis (15-18 August, 2024).

The purpose of the the Pulmonary Hypertension Association’s award is to support research aimed at addressing early diagnosis, education, and improving clinical outcomes and treatments for pulmonary hypertension (PH) patients who may be impacted by health inequities. Awards may be approved for up to a two (2) year period, up to $50,000/year.

Applications for the Pulmonary Hypertension/Pulmonary Vascular Disease (PH/PVD) Fellowship at the University of Pennsylvania for the academic year starting July 2025 are open.

Cereno Scientific, a pioneering biotech developing innovative treatments for rare and common cardiovascular diseases, has joined PVRI as a Roundtable member.

The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School invites applications for an advanced fellowship in pulmonary heart disease starting 1 July 2025.

Rupert Swift, a brave, bold, clever, charismatic young man who embraced life to the full, developed high altitude pulmonary oedema and 3 months later, was diagnosed with functional class 3 pulmonary hypertension. 

Last year Sam, Max, and Harri completed the London Tough Mudder to raise money for the PVRI. After raising an incredible £3,742 which put them in the top three Tough Mudder fundraisers of 2023, they are back this year to compete again joined by Toby and Harrison. 

The PVRI joins the community of physicians, scientists, patients and their families in mourning Dr John Newman’s passing on the 20 February 2024.